Zoliflodacin
Zoliflodacin (development codes AZD0914 and ETX0914) is an experimental antibiotic that is being studied for the treatment of infection with Neisseria gonorrhoeae (gonorrhea).[1] It has a novel mechanism of action which involves inhibition of bacterial type II topoisomerases.[2] It is being developed by Entasis Therapeutics and is (as of 2020) in Phase III clinical trials.[3]
Clinical data | |
---|---|
Other names | AZD0914; ETX0914 |
Pregnancy category |
|
Routes of administration | Oral |
Drug class | Antibiotic |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 97.8% |
Metabolism | Hepatic |
Onset of action |
|
Elimination half-life | 5.3–6.3 h |
Excretion | |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C22H22FN5O7 |
Molar mass | 487.444 g·mol−1 |
3D model (JSmol) | |
| |
|
References
- Taylor SN, Marrazzo J, Batteiger BE, Hook EW, Seña AC, Long J, et al. (November 2018). "Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea". The New England Journal of Medicine. 379 (19): 1835–1845. doi:10.1056/NEJMoa1706988. hdl:1805/19865. PMID 30403954.
- Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, et al. (July 2015). "Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases". Scientific Reports. 5: 11827. Bibcode:2015NatSR...511827B. doi:10.1038/srep11827. PMC 4501059. PMID 26168713.
- "Pipeline". Entasis Therapeutics.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.